Use of vaccinia rabies recombinant for oral vaccination of wildlife.
A vaccinia rabies recombinant virus was constructed and shown to induce the synthesis of rabies virus glycoprotein in infected cells and to induce rabies virus neutralizing antibodies and protection in susceptible animals. Active when orally administered, this recombinant is a good candidate for the development of vaccines for wild animal rabies vectors. This recombinant was found stable, safe for target and non-target animal species, and protective for most of the rabies vectors. After extensive experimental studies conducted under controlled conditions, it as used in limited field trials and in an extensive open field trial. The preliminary results confirmed its basic properties and potential for rabies eradication.
Rhône-Mérieux, Laboratoire IFFA, Lyon, France.
P
P
Desmettre
B
B
Languet
G
G
Chappuis
B
B
Brochier
I
I
Thomas
J P
JP
Lecocq
M P
MP
Kieny
J
J
Blancou
M
M
Aubert
M
M
Artois
D000818:Animals; D000835:Animals, Wild; D004199:Disease Vectors; D011818:Rabies / Q000517:prevention & control / Q000662:veterinary*; D011819:Rabies Vaccines; D014611:Vaccination / Q000662:veterinary*; D014614:Vaccines, Synthetic; D014616:Vaccinia virus / Q000235:genetics / Q000276:immunology
D011819:Rabies Vaccines; D014614:Vaccines, Synthetic